Cargando…
A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space
Introduction: Cannabis extracts are being increasingly used to mitigate chronic pain. Current guidelines for their prescription rely on Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) content as well as the ratio of these major cannabinoids present in the blend. Here we assessed whether these...
Autores principales: | Benredjem, Besma, Pineyro, Graciela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514912/ https://www.ncbi.nlm.nih.gov/pubmed/37745077 http://dx.doi.org/10.3389/fphar.2023.1235255 |
Ejemplares similares
-
Continuous-Flow
Synthesis of Δ(9)-Tetrahydrocannabinol
and Δ(8)-Tetrahydrocannabinol from Cannabidiol
por: Bassetti, Benedetta, et al.
Publicado: (2023) -
Toxicological Properties of Δ(9)-tetrahydrocannabinol and Cannabidiol
por: Černe, Katarina
Publicado: (2020) -
The Effect of Orally Administered Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice
por: Eitan, Adi, et al.
Publicado: (2023) -
Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity
por: Chetia, Swapnali, et al.
Publicado: (2020) -
Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial
por: Zamarripa, C. Austin, et al.
Publicado: (2023)